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Abstract
Angiogenesis is important for tumour vascularisation and growth, and is therefore a promising target for cancer therapy. The present study
reports inhibition of in vitro angiogenesis in human umbilical vein endothelial cells (HUVEC) as well as in rat aortic rings at physiological
concentrations of lycopene, that is, 1–2mmol/l. At a final concentration of 1·15mmol/l, a significant reduction (P , 0·05) in network
branching, that is, junction numbers, the number of tubules and tubule length, was observed in both HUVEC as well as in the rat
aortic rings. The inhibitory effect of lycopene was independent of the presence of the pro-angiogenic agents, vascular endothelial
growth factor and TNF-a. The anti-angiogenic effects of lycopene in the present study were shown at a concentration that should be
achievable by dietary means. These results extend our knowledge of one of the putative anti-cancer actions of lycopene.
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Angiogenesis is one of the prerequisites for tumour growth and
progression(1,2). Without the angiogenic process, a tumour can
only grow 1–2 mm in size. Angiogenesis is therefore a poten-
tial target in suppressing the spread and growth of cancer.
Lycopene (a component of red fruits and vegetables) has
been suggested as an anti-cancer dietary component by both
epidemiological(3–5) as well as experimental studies(6–9). Var-
ious modes of action for lycopene have been suggested for its
anti-carcinogenic effects. These range from its antioxidant
property(10), reduction in DNA damage(7), inhibition of
adhesion, invasion and migration(9), cell cycle arrest(8) and
inhibition of tumour growth(6,11). Although each of these
modes of action is important for tumour interception, angio-
genesis inhibition is considered the most important target for
blocking tumour growth. Recently, on subcutaneous implan-
tation of human androgen-independent prostate carcinoma
PC-3 cells into athymic nude mice, lycopene at concentrations
of 4 and 16 mg/kg inhibited tumour growth while reducing
plasma levels of vascular endothelial growth factor
(VEGF)(11). Angiogenic factors such as VEGF, basic fibroblast
growth factor and TNF-a are secreted by tumour cells in
response to hypoxia and energy depletion, resulting in the
recruitment of endothelial cells and their proliferation to
mediate angiogenesis and hence tumour growth(12).
In the present study, we have examined the effect of lyco-
pene on angiogenesis in vitro. A number of angiogenesis
models have been reported in the literature(13). These assays
are based on the formation of tube-like structures, or pseudo-
tubules, from endothelial cells upon their culture on an angio-
genesis-supporting matrix. One such substrate is Matrigele,
which is the trade name for a solubilised basement membrane
preparation marketed by BD Biosciences (San Jose, CA, USA).
When endothelial cells grow on Matrigele, they produce an
intricate cell network, which is highly suggestive of the micro-
vascular capillary system that provides tissues with nutrients
and oxygen. Structural proteins such as laminin (60 %) and
collagen type IV (30 %) make up the bulk of the Matrigele
matrix and provide cultured cells with the adhesive peptide
sequences they would naturally encounter in vivo. Also
containing proteoglycans, heparin sulphate and entactin, the
unique composition of Matrigele resembles the mammalian
cellular basement membrane and thus provides a biologically
active and physiologically relevant environment for studies of
cell morphology, migration and angiogenesis. Angiogenesis
can also be assessed by way of intricate co-culture of endo-
thelial cells on a feeder layer of fibroblasts in high-priced
ready-to-use angiogenesis kits or by using rat aortic rings.
The latter, an ex vivo assay, involves thin aortic sections to be
cultured on a supportive matrix such as Matrigele and the
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examination of outgrowth of endothelial and non-endothelial
cells over a period of 7–14 d. Microvessel outgrowth from
these primary explants can be quantified in terms of tubule
length and number of junctions within the newly formed net-
work. The rat aortic ring assay closely represents the in vivo
environment of angiogenesis, as it involves both endothelial
and surrounding non-endothelial cells(13). The present study
examines the effect of lycopene on both the above assay
systems.
Materials and methods
All reagents were obtained from Sigma-Aldrich (Gillingham,
Dorset, UK) unless otherwise stated. Cell culture reagents
were obtained from TCS Cellworks (Little Balmer, Bucks,
UK). Matrigele basement membrane preparation was pur-
chased from BD Biosciences. Standard cell culture plastics
were obtained from Greiner Bio-one (Stonehouse, Gloucester,
UK). Specialised culture plastics were obtained from Inte-
grated BioDiagnostics (ibidi; Martinsried, Munich, Bavaria,
Germany). The lycopene powder was a generous gift from
DSM Nutritionals (Kaiseraugst, Switzerland).
Culture of endothelial cells
Pooled human umbilical vein endothelial cells (HUVEC) were
obtained from TCS Cellworks and cultured in complete large
vessel endothelial cell basal medium supplemented with
2 % complete large vessel endothelial cell growth supplement
and antibiotics, as per the manufacturer’s recommendations.
Cells were passaged using a tailored passage kit, including
a buffered rinsing solution, trypsin–EDTA and trypsin block-
ing solution. Incubation took place at 378C in humidified air
containing 5 % CO2. Care was taken not to grow HUVEC
beyond 80 % confluence. All experiments involving HUVEC
were carried out between passages three and six.
Preparation of lycopene
Lycopene was prepared fresh for each set of experiments.
In short, a lycopene stock solution of 5 mM was prepared by
dissolving the crystalline powder (DSM Nutritionals) in freshly
purified tetrahydrofuran with 0·025 % butylated hydroxy-
toluene. Aliquots were stored at 2808C under N2 gas. For
experiments, the lycopene stock was diluted in the ratio
1:10 with fetal calf serum for enhanced stability and vortexed
vigorously for 1 min. Cells were treated with lycopene at
concentrations of 0·58, 1·15 (concentration previously shown
to be achievable after the consumption of tomato products
for 1 week)(14) and 2·3mmol/l. A tetrahydrofuran toxicity
study on HUVEC revealed no effect on cellular viability at
tetrahydrofuran concentrations ,0·25 %.
Rat aortic ring assay
The twenty-four centre wells of a forty-eight-well microtitre
plate were coated with Matrigele. A freshly dissected rat
aorta was placed in PBS solution and cut into 1-mm rings
using sterile scalpel blades in a sterile environment. The
rings were then carefully placed into the Matrigele-coated
wells, one ring per well, and were maintained in Medium
200 containing a low serum growth supplement and 0·3 % of
the anti-fungal agent, amphotericin. The plate was then incu-
bated at 378C in 5 % CO2 for 48 h before treatment. Following
48 h incubation, the rings were treated with lycopene at con-
centrations of 0·58, 1·15, 2·3 and 5mmol/l in supplemented
Medium 200 in duplicates. Control wells were treated with
vehicle only. As outgrowth of cells from the aortic ring
occurs over a period of 6–10 d and lycopene gradually
degrades under cell culture conditions, the treatment
medium was refreshed every day.
Analysis of the rat aortic ring assay
For imaging purposes, the rings were fixed in 10 % phosphate-
buffered formalin (4 % formaldehyde, 0·4 % sodium dihydrogen
orthophosphate and 0·65 % disodium hydrogen phosphate)
and stained with 150ml of a 0·02 % methylene blue solution
for 24 h. The Matrigele was dried under a gentle stream of N2
gas. Images of each well were taken with a FUJI C750UZ digital
camera (FUJIFILM Europe GmbH, Du¨sseldorf, Germany) and
pseudotubule outgrowth was analysed using the angiogenesis
analysis software AngioSys version 1.0 (TCS Cellworks), which
measures tubule length, number of junctions, number of indi-
vidual tubules and total tubule growth area.
Human umbilical vein endothelial cells monoculture assay
HUVEC were grown to 50 % confluence and treated with lyco-
pene at concentrations of 0·58, 1·15 and 2·3mmol/l for 24 h
before seeding onto Matrigele; or with TNF-a at concentrations
of 5, 10 and 20mg/l for 24 h before seeding; or with VEGF at
concentrations of 1, 2, 4 and 8 ng/l upon seeding and for 24 h
before seeding; or simultaneously with lycopene (0·58, 1·15
and 2·3mmol/l) plus 10mg/l TNF-a for 24 h; or with lycopene
at concentrations of 0·58, 1·15 and 2·3mmol/l for 24 h, followed
by exposure to 8 ng/l VEGF upon seeding onto Matrigele.
After incubation with the test compounds, cells were har-
vested using 0·02 % EDTA, pelleted by centrifugation and
duplicate cell counts were performed. A total of 5 £ 103 cells
per well were then seeded into the ibidi m-slide angiogenesis
and incubated for 12–24 h. Exposure to 20mg/l suramine
served as a negative control.
Analysis of angiogenesis
For imaging purposes, pseudotubules were fixed overnight
in 10 % phosphate-buffered formalin and pictures of the
wells were taken by phase contrast microscopy at overall
magnifications of 18·75 £ and 30 £ . The overall length of
the tubule networks and the numbers of junctions were deter-
mined using the angiogenesis analysis software AngioSys
version 1.0 (TCS Cellworks). Good-quality images with a
clear contrast of pseudotubules-to-background are required
for successful image analysis with this program. Identical
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threshold settings were maintained for all images of the same
experiment series to ensure accuracy of the results.
Statistical analysis
Experiments were repeated three times, with triplicate
measurements done on each occasion. Results are therefore
an average of nine measurements. The data sets were com-
pared by paired t test using SPSS 16.0 for Windows (SPSS,
Inc., Chicago, IL, USA), with the significance of difference
set at a level of 0·05.
Results
The rat aortic ring assay closely represents the in vivo environ-
ment of angiogenesis, as it involves endothelial cells as well as
the surrounding non-endothelial cells(13). Treatment of rat
aortic rings with lycopene significantly reduced the pseudotu-
bule network in terms of network length as well as the junc-
tion numbers (Figs. 1 and 2). Fig. 1 shows reduction in
tubule length by 25 and 44 % with lycopene concentration
of 1·15 (P ¼ 0·04, paired t test) and 5mmol/l (P ¼ 0·001),
respectively. The effect on junction numbers was even more
pronounced, with a reduction in network branching of 44 %
at 1·15mmol/l lycopene and a reduction of 43·5 % at the high-
est lycopene concentration of 5mmol/l. The cell outgrowth at
8 d after planting the rings is shown in Fig. 2. The vehicle con-
trol (tetrahydrofuran, Fig. 2(a)) shows a nicely structured
pseudotubule network with clearly defined tubules and regu-
lar branching. All cells appear to be linked into the network,
with no apparent cell sheet formation. With the introduction
of lycopene into wells (Fig. 2(b)–(e)), the regular network
was replaced by a less structured arrangement of cells and
greatly increased formation of cell sheets. The lack of structure
was most obvious in the well with the highest concentration of
lycopene (5mmol/l, Fig. 2(e)), in which seemingly random
cell sheets and irregular junctions replaced the defined pseu-
dotubule network observed in the control well (Fig. 2(a)).
(a)
(b)
(c)
(d)
(e)
Fig. 2. Rat aortic rings treated with lycopene at concentrations of (a) 0,
(b) 0·58, (c) 1·15, (d) 2·3 and (e) 5mmol/l in tetrahydrofuran.
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Fig. 1. Tubule length ( ) and junction numbers ( ) of the cell outgrowth of
rat aortic rings treated with 1·15 and 5mmol/l lycopene relative to the
untreated control (0mmol/l lycopene). Values are means of three experiments
and standard deviations. Mean values were significantly different: *P,0·05,
**P,0·01 (comparison with control was done using a paired t test).
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Effect of lycopene on human umbilical vein endothelial
cells monoculture in Matrigele
Fig. 3 shows that with increasing concentrations of lycopene,
the overall tubule length of the network as well as junction
numbers within this network were reduced. Although
the lowest concentration of 0·58mmol/l lycopene exerted no
significant effect, 1·15mmol/l of lycopene significantly
reduced overall network length by 11 % (P ¼ 0·04, paired t
test) and junction numbers by 17 % (P ¼ 0·05) compared to
the control. The highest concentration of lycopene at
2·3mmol/l further reduced network formation and junction
numbers, resulting in a total reduction of 24 % (P ¼ 0·03)
and 33 % (P ¼ 0·007), respectively. This is also illustrated in
Fig. 4, which shows representative images of the tubule net-
work formed by untreated HUVEC (Fig. 4(a)), as well as
after exposure of HUVEC to 2·3mmol/l (Fig. 4(b)) and
20mg/l suramine (Fig. 4(c) – negative control).
Effect of TNF-a and lycopene on angiogenesis
The effect of TNF-a, a known pro-angiogenic factor, alone
and in combination with lycopene was assessed. HUVEC
were pre-treated with either TNF-a alone or in combination
with varying concentrations of lycopene for 24 h before
seeding onto Matrigele in the m-slide angiogenesis. The initial
TNF-a treatment course was used to establish a suitable
concentration for HUVEC exposure in combination with
lycopene. Cells were exposed to TNF-a at 5, 10 and 20mg/l.
Fig. 5(a) shows the effect of TNF-a on overall network
length and junction numbers. TNF-a increased both the total
tubule length and junction numbers at all concentrations.
The latter increased by 14 % at 5mg/l TNF-a and by 18 %
at 10mg/l (P ¼ 0·002) of the inflammatory cytokine, whereas
tubule length increased by 10 and 16 %, respectively.
The 20mg/l concentration of TNF-a did not result in a signifi-
cant further increase of network formation compared to that
at 10mg/l. As a result, the 10mg/l concentration of TNF-a
was used in the subsequent experiments with lycopene.
When cells were exposed to 10mg/l TNF-a and lyco-
pene simultaneously for 24 h, there was a significant reduction
in network branching (junction numbers, number of
tubules and tubule length) at both lycopene concentration
of 1·15 (P ¼ 0·05) and 2·3mmol/l (P ¼ 0·01, Fig. 5(b) and
(c)). Lower concentrations of lycopene (0·58mmol/l) did
not appear to affect the assessed angiogenic parameters
significantly.
(a)
(b)
(c)
Fig. 4. (a) The pseudotubule network in an untreated control well. Effect of
(b) 2·3mmol/l lycopene and (c) 20mg/l suramine on angiogenesis of human
umbilical vein endothelial cells is shown.
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Fig. 3. Effect of lycopene on angiogenesis of human umbilical vein endo-
thelial cells. Cells were treated with increasing concentrations of lycopene for
24 h before seeding onto Matrigele. The bar chart shows total tubule length
( ) and junction numbers ( ) as a percentage of the control values and
standard deviations. Mean values were significantly different from control:
*P,0·05, **P,0·01.
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Effect of vascular endothelial growth factor and lycopene
on angiogenesis
HUVEC were exposed to increasing concentrations of VEGF at
concentrations of 1, 2, 4 and 8 ng/l, either 24 h before or while
seeding onto Matrigele. An increase in overall tubule length,
as well as tubule numbers and junction numbers, could be
observed with VEGF exposure, as is illustrated in Fig. 6. Over-
all tubule length peaked at 4 ng/l VEGF with a 12 % increase,
whereas VEGF at 8 ng/l resulted in an overall increase in
tubule and junction numbers of approximately 20 %
(Fig. 6(a)). There was no significant difference in the effect
of VEGF on the angiogenic activity of HUVEC pre-treated
with VEGF for 24 h compared to exposure to VEGF upon
seeding onto Matrigele (results not shown).
Pre-incubation of HUVEC with lycopene for 24 h prior
to exposure of cells to 8 ng/l VEGF resulted in a reduction
of both tubule length and junction numbers. Exposure of
HUVEC to the lowest lycopene concentration of 0·58mmol/l
abrogated the stimulatory effect of VEGF on both the
junction numbers and overall network length, but results
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Fig. 5. The effect of TNF-a on angiogenesis of human umbilical vein endo-
thelial cells. (a) Cells were treated with increasing concentrations of TNF-a
for 24 h before seeding onto Matrigele. Total tubule length ( ) and junction
numbers ( ) are shown as a percentage of the control values and standard
deviations. The effect of lycopene on (b) total tubule length, (c) junction
numbers, both in the presence ( ) and absence ( ) of TNF-a are shown.
The bar chart shows the ratio of the control values and standard deviations.
Mean values were significantly different from control: *P,0·05, **P,0·01.
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Fig. 6. The effect of vascular endothelial growth factor (VEGF) on angio-
genesis of human umbilical vein endothelial cells (HUVEC). (a) Cells were
exposed to increasing concentrations of VEGF upon seeding onto Matrigele.
The bar chart shows the number of tubules ( ), junctions ( ) and total
tubule length ( ) as a ratio of the control values and standard deviations.
The effect of lycopene alone and lycopene þ 8 ng/l VEGF on angiogenesis of
HUVEC is shown in (b) and (c). Cells were pre-treated with increasing
concentrations of lycopene for 24 h and exposed to 8 ng/l VEGF upon seed-
ing onto Matrigele. The effect of lycopene on (b) total tubule length and (c)
junction numbers, both in the presence ( ) and absence ( ) of VEGF. Data
points are presented as a ratio of the control values and standard deviations.
Mean values were significantly different from control: *P,0·05, **P,0·01.
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were statistically significant for tubule length only (P ¼ 0·05).
With increasing lycopene concentrations, both parameters
decreased further (Fig. 6(b) and (c)), resulting in a maximum
reduction of tubule length by 15 % at 2·3mmol/l (P ¼ 0·008)
and 7 % at 1·15mmol/l (P ¼ 0·03) lycopene relative to the
untreated control. The reduction in junction numbers was
more pronounced at 2·3mmol/l lycopene (29 % reduction,
P ¼ 0·03) than at 1·15mmol/l (24 % reduction, P ¼ 0·05). Lyco-
pene appeared to have a greater inhibitory effect on the
network branching, that is, junction numbers, mediated by
exposure to VEGF than on the overall tubule length.
Discussion
Tumours can remain dormant for years, during which time
their size is maintained by a balance between apoptosis and
proliferation of cells. This, however, maintains the tumour
size at the limit for simple diffusion of nutrients and gases
like CO2 and O2. To increase its growth, tumour cells secrete
angiogenic factors, which lead to the recruitment of endo-
thelial cells and their proliferation for neovascularisation.
Anti-angiogenic intervention is therefore considered important
in cancer interception because of the crucial role that neovas-
cularisation plays in the pathology of cancer. In the present
investigation, lycopene at a final concentration $1·15mmol/l
significantly inhibited the angiogenic process in all the test
systems, that is, rat aortic ring assay as well as TNF-a- and
VEGF-stimulated angiogenesis in HUVEC. To extrapolate
these results to an in vivo situation, it is important to consider
whether the endothelium is likely to be exposed to such con-
centrations in vivo. Both inter-individual differences in
response and bioavailability from different tomato products
will overall influence the changes in plasma lycopene after
supplementation(15,16). Plasma levels of up to 1·2mmol/l
have been obtained with the use of supplements at a dose
of 15 mg lycopene/d (equivalent to 600 g of raw tomatoes or
100 g of tomato paste) for 3 months(17). A similar increase in
plasma lycopene was observed after the consumption of
200 g tomato soup plus 230 g canned tomatoes providing
approximately 46 mg lycopene/d for 1 week(14). An increase
in plasma lycopene to approximately 1·2mmol/l has also
been reported after supplementation with tomato sauce-
based pasta for 3 weeks providing approximately 30 mg lyco-
pene/d(18). However, several other studies with supplements
or foods containing a lycopene content of 6–25 mg and a dur-
ation period ranging from 1 to 8 weeks have shown a maxi-
mum increase of plasma lycopene to 0·80mmol/l(19–22). It is
therefore important to note that, although levels of up to
1·2mmol/l can be achieved in vivo, these levels are likely to
be achieved when individuals are either supplemented for a
longer period of time or with high concentrations of a more
bioavailable form of lycopene. In our previous study, when
participants were allowed to choose from different red fruits
and vegetables providing approximately 45 mg lycopene/d,
mean plasma lycopene concentrations were raised to
0·85mmol/l only, and the change was lower in smokers com-
pared to non-smokers(23). Lycopene bioavailability is known
to vary between tomato products, and bioavailability is
higher from processed tomatoes compared to raw toma-
toes(19,24,25). Both processing and presence of fat have been
show to increase the bioavailability of lycopene(25). However,
prolonged heating can also reduce the carotenoid content,
especially if peeled tomatoes are used(26). Furthermore, the
lycopene content of tomato products can also vary(27). Obser-
vational studies have reported a reduction in risk of cancer
incidence, especially that of prostate cancer, with the con-
sumption of approximately 200 g tomato products per
day(28). An increase in plasma lycopene to 0·55mmol/l has
been reported with the consumption of 300 g raw tomatoes
for 7 d and up to 0·80mmol/l with consumption of 60 g
tomato puree(19). In a prospective study, patients with aggres-
sive prostate cancer were reported to show a plasma lycopene
concentration of 356 ng/ml (0·66mmol/l) compared to controls
with plasma values of 388 ng/ml (0·72mmol/l)(29). In our present
study, at a test concentration of 0·58mmol/l, very little effect was
observed on angiogenesis. Also, we did not examine the effect
within a concentration range of 0·58–1·15mmol/l. However, it is
possible that a small increment in the concentration of lycopene
.0·6mmol/l might have shown a significant effect and perhaps
highlighted the minimum lycopene concentration that is likely
to intercept the angiogenic process. Baseline plasma concen-
trations of 0·50–0·60mmol/l (equivalent to the lowest concen-
tration used in the present study) has been reported by several
studies(14,18,19,30); however, few studies have also reported
plasma levels of lycopene as low as 0·34mmol/l with their habit-
ual diet(20,21). Likewise, low lycopene levels reported for
cancer patients and controls also vary between studies(29,31–33).
The amount of lycopene that may be required to affect angio-
genesis in vivo is therefore likely to vary between individuals.
It is therefore difficult to speculate on the amount of tomato
products that can be recommended for a possible angiogenic
interception in vivo. The results of our study therefore can
only highlight that at a baseline concentration that has been
reported by several studies, that is, 0·58mmol/l, lycopene has
a minimal effect on angiogenesis; however, .1mmol/l lyco-
pene can significantly inhibit angiogenesis in vitro.
b-Carotene and lycopene are the two major carotenoids in
tomatoes as well as in human plasma(18,19,23,27). In one
study, oral b-carotene supplementation of mice at 0·25 % con-
centration for 2 weeks is reported to inhibit angiogenesis
evoked by HeLa and SKv-t tumour cell lines, but increased
the angiogenesis induced by lymphocytes(34). Another study
examined a concentration range of 0·3–3mmol/l of b-carotene
and reported an increase in basic fibroblast growth factor-
induced angiogenesis in a mouse Matrigele model at a con-
centration of 3mmol/l of the carotenoid(35). In contrast, there
are reports of a dose-dependent inhibition of tumour-specific
angiogenesis in HUVEC and rat aortic rings by b-carotene at
concentration range of 1–10mg/l (1·8–18mmol/l) in vitro (36)
as well as in an in vivo mouse model(37). A recent study
reported a dose-related inhibition of angiogenesis by lyco-
pene in HUVEC at a concentration range of 1–10mmol/l(38).
In agreement with their results, our experiments also show
an inhibitory effect at concentrations .1mmol/l and a small,
though mostly insignificant, effect at concentrations as low
as 0·58mmol/l. In the study by Sahin et al.(38), HUVEC were
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grown in a medium supplemented with VEGF and fibroblast
growth factor, and both these are considered important angio-
genic growth factors. Angiogenesis inhibitors can either act
by inhibition of the formation of these growth factors or
through blocking of their action(12). In the previous studies,
in vivo supplementation of lycopene was shown to reduce
the plasma levels of VEGF(11) and inhibit the VEGF expression
by nude mice injected with tumour cells(37). VEGF levels are
reported to be raised in cancer patients(39). The present
study has demonstrated a slight but significant reduction
in VEGF-mediated angiogenesis of HUVEC after 24 h pre-
treatment of cells with lycopene, both with regard to overall
pseudotubule network length and junction numbers. These
effects were seen at concentrations as low as 1·15mmol/l,
but were most pronounced at the higher concentration of
2·3mmol/l of lycopene.
The pro-inflammatory cytokine, TNF-a, has also been
shown to act as an autocrine growth factor for tumour angio-
genesis(40) and to affect the angiogenesis process directly(40,41)
as well as through its effects on VEGF formation(41,42). The
present study has demonstrated angiogenesis interception by
lycopene in both TNF-a-mediated (Fig. 5(b) and (c)) as well
as VEGF-induced angiogenic potential of HUVEC (Fig. 6(b)
and (c)). With circulating levels of TNF-a being raised in pros-
tate cancer(43,44), lycopene might be beneficial in reducing the
pro-angiogenic action of TNF-a in these patients. Epidemiolo-
gical prospective data and dietary case–control studies
suggest that a high intake of tomatoes and tomato-based
products, with a resulting high plasma concentration of
circulating lycopene, is associated with a highly significant
reduction in the risk of cancer, in particular prostate
cancer(45). This has been found to be especially true for the
more aggressive forms of prostate cancer. Also, lower serum
and prostatic tissue levels of lycopene were demonstrated
in men with prostate cancer when compared to healthy
age-matched controls(29,46). Likewise, lower plasma lycopene
levels have been reported in patients with cervical
cancer(31,32) and colorectal adenomas(47). The anti-angiogenic
activity of lycopene is therefore a likely candidate not just
for prostate but also for other cancers owing to the crucial
role that angiogenesis plays in growth and sustainment of
tumours. It has been suggested that agents that exhibit both
anti-angiogenic as well as anti-metastatic activity are likely
to evoke a greater effect on tumour response/therapy than
treatment with a single agent of these classes(48). The results
of the present study combined with previously published
anti-metastatic effects of lycopene(49–51) not only support
the findings of observational studies that show an inverse
correlation between tomato consumption and risk of cancer
but also offer a therapeutic hope for cancer inhibition.
Angiogenesis is a fundamental step in the transition of
tumours from a quiescent to a malignant state, and is a
requirement for both tumour progression and metastasis(52).
The tumour vasculature has been identified as a strong
prognostic marker for tumour grading(53). Endothelial cells
represent a suitable target for anti-angiogenic treatment
because they are non-transformed host cells and unlikely to
acquire resistance to treatment compounds. Being part of
the circulatory system, they also facilitate administration of a
given therapeutic agent. Natural products are an attractive
option for tumour interception, especially if they can be
shown to intercept the tumorigenic processes at biologically
achievable concentrations. The present investigation has
demonstrated an inhibitory effect of lycopene on the
angiogenic response in HUVEC and rat aortic rings at concen-
trations possible to be achievable in vivo after tomato product
consumption. As lycopene was shown to exhibit its
anti-angiogenic effects at achievable concentrations in vivo,
it indeed can be regarded as a promising anti-angiogenic com-
pound and can also explain why this compound has been
highlighted as an important anti-cancer dietary component.
Further in vivo studies are however warranted to confirm
the in vitro effects of lycopene seen in the present study.
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